For US Healthcare Professionals Only IzervayECP.com Full Prescribing Information References
For US Healthcare
Professionals Only

Assess GA
progression risks

Evaluate the factors for geographic atrophy (GA)
progression that elevate treatment urgency.

Keep these risk factors on your radar

Multifocal lesions often grow faster than unifocal lesions.2
Images courtesy of Dr. Mohammad Rafieetary ("Multifocal") and Dr. Julie Rodman ("Unifocal").
Extrafoveal lesions often grow faster than foveal lesions.2
Images courtesy of Dr. Julie Rodman.
Hyperfluorescence highlights areas at risk for progression as a result of lipofuscin accumulation.2,3
Images courtesy of Dr. Mary Beth Yackey.
GA often develops bilaterally, at which point it may grow faster.2
Images courtesy of Dr. Julie Rodman.

Patients at risk of rapid progression*

caption
OD
 caption
OS
 caption
OD
 caption
OS
 caption
OD
 caption
OS
caption
OD
 caption
OS
 caption
OD
 caption
OS
 caption
OD
 caption
OS

Clinical History
  • 63-year-old White female
  • BCVA OS declined from 20/25-2 to 20/30
  • Patient complains of difficulty reading at night
Additional Factors
  • Mother had AMD

Patient may seem to have decent visual acuity, but BCVA does not necessarily correlate to visual function.1,2

  • Multifocal, extrafoveal lesions OU are visible on FAF and OCT
  • OD FAF shows diffuse hyperfluorescence around lesions
  • Multiple bands of choroidal hypertransmission OU

The presence of bilateral, multifocal, extrafoveal lesions and hyperfluorescent areas coupled with a family history of AMD increases this patient’s risk of rapid progression.2

An early referral for IZERVAY may help slow
the impending irreversible effects of GA.2,3,8

*These case studies feature real scans, but some historical details have been modified for educational purposes.

AMD=age-related macular degeneration.

caption
OD
 caption
OS
 caption
OS, BASELINE
 caption
OS, 1 YEAR FROM BASELINE
 caption
OS, 2 YEARS FROM BASELINE
caption
OD
 caption
OS
 caption
OS, BASELINE
 caption
OS, 1 YEAR FROM BASELINE
 caption
OS, 2 YEARS FROM BASELINE

Clinical History
  • 75-year-old Asian female
  • Cataract surgery with PCIOL OS 20/40, OD 20/400
  • Expresses concern about losing vision in left eye
Additional Factors
  • COPD

With GA significantly affecting vision in the right eye, it is imperative to stay vigilant for risk factors in the fellow eye.2

  • Foveal lesion OD and multifocal lesions OS
  • Increase in choroidal transmission on OS OCT over 3 years

The presence of multifocal lesions, hyperfluorescent areas, and previous rate of progression elevates this patient’s risk of further progression in both eyes.2

This patient is in urgent need of a referral to a retinal specialist who may recommend IZERVAY to help slow the GA progression.8

*These case studies feature real scans, but some historical details have been modified for educational purposes.

COPD=chronic obstructive pulmonary disease; PCIOL=posterior chamber intraocular lens.

caption caption caption
caption caption caption

Clinical History
  • 69-year-old Hispanic male
  • Visual acuity 20/25 OD, 20/20 OS
  • Complains of blurry vision and difficulty driving at night
  • OS has intermediate AMD
Additional Factors
  • Smoker for 25 years
  • Hypertension

GA could be missed on CFP but is more apparent on FAF and OCT.

  • Multifocal lesions with hyperfluorescent areas on FAF
  • Choroidal hypertransmission OCT with GA encroaching central fovea

This patient presents with multiple risk factors for GA progression: multifocal, extrafoveal lesions with hyperfluorescent areas.2

This patient’s timely diagnosis optimizes the
opportunity to get ahead of GA progression.2,3,8

*These case studies feature real scans, but some historical details have been modified for educational purposes.

AMD=age-related macular degeneration.

Download Case Studies

Act Early

A prompt referral for IZERVAY can make a significant difference.8

IMPORTANT SAFETY INFORMATION AND INDICATION

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Neovascular AMD

  • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.

Increase in Intraocular Pressure

  • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Neovascular AMD

  • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.

Increase in Intraocular Pressure

  • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information.

Images courtesy of Heidelberg Engineering, Dr. Julie Rodman, and Dr. Mohammad Rafieetary.